Premium
Randomised clinical trial: rifaximin improves health‐related quality of life in cirrhotic patients with hepatic encephalopathy – a double‐blind placebo‐controlled study
Author(s) -
Sanyal A.,
Younossi Z. M.,
Bass N. M.,
Mullen K. D.,
Poordad F.,
Brown R. S.,
Vemuru R. P.,
Mazen Jamal M.,
Huang S.,
Merchant K.,
Bortey E.,
Forbes W. P.
Publication year - 2011
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2011.04808.x
Subject(s) - rifaximin , medicine , hepatic encephalopathy , cirrhosis , lactulose , placebo , gastroenterology , quality of life (healthcare) , randomized controlled trial , encephalopathy , liver disease , alternative medicine , nursing , pathology , microbiology and biotechnology , biology , antibiotics
Aliment Pharmacol Ther 2011; 34: 853–861 Summary Background Hepatic encephalopathy (HE) is a brain disorder that often results from cirrhosis due to viral hepatitis, metabolic and alcohol‐related liver disease, and is characterised by cognitive, psychiatric and motor impairments. Recurrent bouts of overt HE negatively impact daily functioning and quality of life. Aim To evaluate the effect of rifaximin on health‐related quality of life (HRQL) in cirrhotic patients with HE. Methods Patients with cirrhosis in remission from HE (Conn score = 0 or 1) and a documented history of recurrent HE episodes (≥2 within 6 months of screening) were randomised to rifaximin 550 mg twice daily ( N = 101) or placebo ( N = 118) for 6 months. Concomitant lactulose was permitted during the study. The Chronic Liver Disease Questionnaire (CLDQ) was administered every 4 weeks, and time for occurrence of HE breakthrough was recorded. A longitudinal analysis using time‐weighted averages of the CLDQ scores normalised by days on study therapy was used to evaluate the effect of treatment on HRQL, and between HE outcomes (HE recurrence, yes/no) irrespective of treatment. Results The time‐weighted averages of the overall CLDQ score and each domain score were significantly higher in the rifaximin group vs. placebo ( P ‐values ranged from 0.0087 to 0.0436); and were significantly lower in patients who experienced HE breakthrough compared to those who remained in remission ( P ‐values were <0.0001). Conclusion Rifaximin significantly improved HRQL in patients with cirrhosis and recurrent hepatic encephalopathy. A lower HRQL may predict recurrence of hepatic encephalopathy (ClinicalTrials.gov identifier NCT00298038).